Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Bilal A Siddiqui; Brian F Chapin; Sonali Jindal; Fei Duan; Sreyashi Basu; Shalini S Yadav; Ai-Di Gu; Alexsandra B Espejo; Michelle Kinder; Curtis A Pettaway; John F Ward; Rebecca S S Tidwell; Patricia Troncoso; Paul G Corn; Christopher J Logothetis; Roland Knoblauch; Natalie Hutnick; Marco Gottardis; Charles G Drake; Padmanee Sharma; Sumit K Subudhi

doi:10.1136/jitc-2022-006262

Article info

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Authors

Bilal A Siddiqui Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Brian F Chapin Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Sonali Jindal The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Fei Duan The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Sreyashi Basu The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Shalini S Yadav The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Ai-Di Gu The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Alexsandra B Espejo The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Michelle Kinder Janssen Research & Development, Spring House, Pennsylvania, USA PubMed articles Google scholar articles
Curtis A Pettaway Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
John F Ward Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Rebecca S S Tidwell Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Patricia Troncoso Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Paul G Corn Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Christopher J Logothetis Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Roland Knoblauch Janssen Research & Development, Spring House, Pennsylvania, USA PubMed articles Google scholar articles
Natalie Hutnick Janssen Research & Development, Spring House, Pennsylvania, USA PubMed articles Google scholar articles
Marco Gottardis Janssen Research & Development, Spring House, Pennsylvania, USA PubMed articles Google scholar articles
Charles G Drake Janssen Research & Development, Spring House, Pennsylvania, USADepartment of Medicine, Columbia University Medical Center, New York, New York, USADepartment of Urology, Columbia University Medical Center, New York, New York, USA PubMed articles Google scholar articles
Padmanee Sharma Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAThe Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Sumit K Subudhi Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles

Citation

Siddiqui BA, Chapin BF, Jindal S, et al

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Journal for ImmunoTherapy of Cancer 2023;11:e006262. doi: 10.1136/jitc-2022-006262

Online issue publication

October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password